[go: up one dir, main page]

CL2018001065A1 - Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih - Google Patents

Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih

Info

Publication number
CL2018001065A1
CL2018001065A1 CL2018001065A CL2018001065A CL2018001065A1 CL 2018001065 A1 CL2018001065 A1 CL 2018001065A1 CL 2018001065 A CL2018001065 A CL 2018001065A CL 2018001065 A CL2018001065 A CL 2018001065A CL 2018001065 A1 CL2018001065 A1 CL 2018001065A1
Authority
CL
Chile
Prior art keywords
union
prevention
treatment
triespecific
binding proteins
Prior art date
Application number
CL2018001065A
Other languages
English (en)
Inventor
Jochen Kruip
Huawei Qiu
Christian Beil
Jochen Beninga
Christian Lange
Zhi-Yong Yang
Gary J Nabel
Ling Xu
Ronnie Wei
Ercole Tao
Wulf Dirk Leuschner
Mark Connors
John R Mascola
Richard A Koup
Jinghe Huang
Nicole A Doria-Rose
Tongqing Zhou
Peter D Kwong
Young Do Kwon
Amarendra Pegu
Mangaiarkarasi Asokan
Asokan Mangaiarkarasi
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of CL2018001065A1 publication Critical patent/CL2018001065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

EN LA PRESENTE MEMORIA SE PROPORCIONAN QUE COMPRENDEN PROTEÍNAS DE UNIÓN TRIESPECÍFICAS Y/O TRIVALENTES QUE COMPRENDEN CUATRO CADENAS POLIPEPTIDICAS QUE FORMAN TRES SITIOS DE UNIÓN A ANTÍGENO QUE SE UNEN ESPECÍFICAMENTE A UNA O MÁS PROTEÍNAS DIANA DE¡ VIH O UNO O MÁS RECEPTORES DE CÉLULAS T, EN DONDE UN PRIMER PAR DE POLIPÉPTIDOS QUE FORMAN LA PROTEÍNA DE UNIÓN POSEE DOMINIOS VARIABLES DUALES QUE TIENEN UNA ORIENTACIÓN CRUZADA Y EN DONDE UN SEGUNDO PAR DE POLIPÉPTIDOS QUE FORMAN LA PROTEÍNA DE UNIÓN POSEE UN SOLO DOMINIO VARIABLE. TAMBIÉN SE PROPORCIONAN EN LA PRESENTE MEMORIA MÉTODOS PARA PREPARAR PROTEÍNAS DE UNIÓN TRIESPECÍFICAS Y/O TRIVALENTES Y USOS DE TALES PROTEÍNAS DE UNIÓN PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE VIH/SIDA.
CL2018001065A 2015-10-25 2018-04-23 Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih CL2018001065A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
CL2018001065A1 true CL2018001065A1 (es) 2018-11-23

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001065A CL2018001065A1 (es) 2015-10-25 2018-04-23 Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih

Country Status (31)

Country Link
US (3) US20190054182A1 (es)
EP (2) EP3819310A1 (es)
JP (3) JP7169190B2 (es)
KR (1) KR102687212B1 (es)
CN (4) CN117069855A (es)
AR (1) AR106466A1 (es)
AU (2) AU2016347058B2 (es)
BR (1) BR112018008011A2 (es)
CA (1) CA3002664A1 (es)
CL (1) CL2018001065A1 (es)
CO (1) CO2018005337A2 (es)
CR (1) CR20180288A (es)
DO (1) DOP2018000102A (es)
EA (1) EA201891028A1 (es)
ES (1) ES2894304T3 (es)
HK (1) HK1253385A1 (es)
HR (1) HRP20211528T1 (es)
HU (1) HUE056608T2 (es)
IL (2) IL301140A (es)
MA (1) MA42641A1 (es)
MX (2) MX2018005048A (es)
MY (1) MY192278A (es)
PE (1) PE20181167A1 (es)
PH (1) PH12018500873A1 (es)
PL (1) PL3365366T3 (es)
RS (1) RS62437B1 (es)
SG (1) SG11201803324VA (es)
SI (1) SI3365366T1 (es)
TW (3) TW202442675A (es)
UY (1) UY36965A (es)
WO (1) WO2017074878A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
CN106459186B (zh) * 2014-02-28 2021-02-02 美国卫生和人力服务部 针对hiv-1 v1v2 env区域的广谱中和性单克隆抗体
JP7169190B2 (ja) * 2015-10-25 2022-11-10 サノフイ Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
US11236152B2 (en) 2015-11-03 2022-02-01 The United States of America, as represented by the Sectetary, Department of Health and Human Services Neutralizing antibodies to HIV-1 GP41 and their use
AU2017248671B2 (en) * 2016-04-13 2024-06-20 Sanofi Trispecific and/or trivalent binding proteins
DK3443006T5 (da) 2016-04-13 2024-09-16 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
CN111788225B (zh) * 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2019123262A1 (en) * 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
TWI745643B (zh) * 2017-12-21 2021-11-11 紐約市哥倫比亞大學理事會 雙專一性hiv-1-中和性抗體
EP3737949A1 (en) 2018-01-12 2020-11-18 Genzyme Corporation Methods for the quantitation of polypeptides
WO2019226829A1 (en) 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
BR112021006558A2 (pt) * 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
US20220025021A1 (en) * 2018-11-21 2022-01-27 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
MX2021012386A (es) 2019-04-09 2022-01-18 Sanofi Sa Proteínas de union triespecíficas, métodos y usos de las mismas.
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
BR112022007664A2 (pt) 2019-10-25 2022-08-09 Sanofi Sa Métodos para analisar o pareamento incorreto de cadeias em proteínas de ligação multiespecíficas
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
BR112023003366A2 (pt) 2020-08-25 2023-05-09 Gilead Sciences Inc Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
EP2316951A1 (en) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9249226B2 (en) 2010-06-09 2016-02-02 Genmab A/S Antibodies against human CD38
WO2012065055A2 (en) 2010-11-12 2012-05-18 The Rockefeller University Fusion proteins for hiv therapy
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
ES2895523T3 (es) * 2011-05-17 2022-02-21 Univ Rockefeller Anticuerpos neutralizantes del virus de inmunodeficiencia humana y métodos de uso de los mismos
WO2013070565A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
WO2013070776A1 (en) 2011-11-07 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing gp41 antibodies and their use
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
IN2015MN00139A (es) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
JP6898060B2 (ja) 2012-12-13 2021-07-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物およびその使用方法
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
EA036577B1 (ru) 2013-11-04 2020-11-25 Икнос Сайенсиз Са Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов
PT3122781T (pt) 2014-03-28 2020-03-05 Xencor Inc Anticorpos biespecíficos que se ligam a cd38 e cd3
DK3189132T3 (da) 2014-09-04 2020-08-10 Stemcell Tech Inc Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EP3298389B1 (en) 2015-05-20 2021-09-29 Quantum-Si Incorporated Method of determining the sequence of a nucleic acid using time resolved luminescence
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
EA201890782A1 (ru) 2015-09-22 2018-09-28 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ перенацеливания t-клеток для лечения инфекции hiv
JP7169190B2 (ja) 2015-10-25 2022-11-10 サノフイ Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
TWI814056B (zh) 2015-12-15 2023-09-01 美商基利科學股份有限公司 人類免疫不全病毒中和抗體
DK3443006T5 (da) 2016-04-13 2024-09-16 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
AU2017248671B2 (en) 2016-04-13 2024-06-20 Sanofi Trispecific and/or trivalent binding proteins
WO2018120842A1 (zh) 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3601334A4 (en) 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
BR112021006558A2 (pt) 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
EP3365366B1 (en) 2021-07-14
CN109311966B (zh) 2023-03-10
AU2024200395A1 (en) 2024-04-11
MX2018005048A (es) 2018-09-06
MX2022014631A (es) 2023-01-11
AU2016347058A1 (en) 2018-06-14
BR112018008011A2 (pt) 2018-10-30
TWI750139B (zh) 2021-12-21
IL258822B2 (en) 2023-08-01
JP2021072847A (ja) 2021-05-13
TW202442675A (zh) 2024-11-01
IL301140A (en) 2023-05-01
KR20180063336A (ko) 2018-06-11
WO2017074878A1 (en) 2017-05-04
TW201730210A (zh) 2017-09-01
KR102687212B1 (ko) 2024-07-19
EP3819310A1 (en) 2021-05-12
CN116789841A (zh) 2023-09-22
SI3365366T1 (sl) 2022-02-28
SG11201803324VA (en) 2018-05-30
CR20180288A (es) 2018-09-11
US20190054182A1 (en) 2019-02-21
HRP20211528T1 (hr) 2021-12-24
AR106466A1 (es) 2018-01-17
US11129905B2 (en) 2021-09-28
UY36965A (es) 2017-05-31
TW202219064A (zh) 2022-05-16
RS62437B1 (sr) 2021-11-30
CA3002664A1 (en) 2017-05-04
MY192278A (en) 2022-08-16
ES2894304T3 (es) 2022-02-14
CN116675776A (zh) 2023-09-01
JP2018537966A (ja) 2018-12-27
US11779651B2 (en) 2023-10-10
AU2016347058B2 (en) 2023-11-09
PE20181167A1 (es) 2018-07-19
US20200054765A1 (en) 2020-02-20
IL258822B1 (en) 2023-04-01
PL3365366T3 (pl) 2022-01-31
CO2018005337A2 (es) 2018-07-10
NZ742825A (en) 2024-04-26
JP7169190B2 (ja) 2022-11-10
HUE056608T2 (hu) 2022-02-28
CN117069855A (zh) 2023-11-17
EP3365366A1 (en) 2018-08-29
MA42641A1 (fr) 2019-03-29
WO2017074878A8 (en) 2018-05-24
DOP2018000102A (es) 2018-11-30
CN109311966A (zh) 2019-02-05
IL258822A (en) 2018-06-28
EA201891028A1 (ru) 2019-02-28
US20220226495A1 (en) 2022-07-21
JP2023085476A (ja) 2023-06-20
PH12018500873A1 (en) 2018-11-12
HK1253385A1 (zh) 2019-06-14
JP7328267B2 (ja) 2023-08-16

Similar Documents

Publication Publication Date Title
CL2018001065A1 (es) Proteínas de unión triespecificas y/o trivalentes para la prevención o el tratamiento de la infección por vih
CO2018012107A2 (es) Proteínas de unión triespecíficas y/o trivalentes
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
EA201892386A1 (ru) Химерные нейротоксины
PE20170767A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
PH12018501429B1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
ECSP18039758A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
AR118602A1 (es) Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih
ECSP18084491A (es) Proteínas de unión triespecíficas y/o trivalentes
AR108210A1 (es) Proteínas de unión triespecíficas y/o trivalentes
CO2021014988A2 (es) Proteínas de unión trispecificas y/o trivalentes utilizando el formato de dominio cruzado sobre dual variable (codv) para el tratamiento de la infección por vih
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
UA114758U (xx) Полімерна гелева композиція для відновлення пошкодженої шкіри
SG10201808583SA (en) Hemostatic pharmaceutical composition
EA202090225A2 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp